Hostname: page-component-6bf8c574d5-b4m5d Total loading time: 0 Render date: 2025-02-20T23:58:40.539Z Has data issue: false hasContentIssue false

Will Chemical Packages be the only Future for Biotechnology? Why the Bayer-Monsanto Merger Could be a Good Opportunity to Put Things in the Right Place

Published online by Cambridge University Press:  20 January 2017

Justo Corti Varela*
Affiliation:
Universidad CEU San Pablo, Madrid
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This section aims to update readers on decisions related to marketing products of modern biotechnology (e.g., GMOs, animal clones) at EU level and on national measures concerning their production. Special attention is devoted to problems of competence between Member States and the EU in regulating biotechnology issues; the institutional dynamics of decision making regarding products derived from modern biotechnology; the relationship between the EFSA and the EU institutions on green biotech-related issues; the evolution of EU regulatory framework and of national attitudes towards the risks and benefits of biotechnology derived products and their production. This section will also delve into the interaction between the EU legislation and WTO law regarding advances in the application of biotechnology within the agri-food value chain.

Type
Reports
Copyright
Copyright © Cambridge University Press 2016